LAT1 (SLC7A5) overexpression in negative her2 group of breast cancer: A potential therapy target

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F62156489%3A43210%2F20%3A43917989" target="_blank" >RIV/62156489:43210/20:43917989 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.31557/APJCP.2020.21.5.1453" target="_blank" >http://dx.doi.org/10.31557/APJCP.2020.21.5.1453</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.31557/APJCP.2020.21.5.1453" target="_blank" >10.31557/APJCP.2020.21.5.1453</a>

Jazyk výsledku

angličtina

Název v původním jazyce

LAT1 (SLC7A5) overexpression in negative her2 group of breast cancer: A potential therapy target

Popis výsledku v původním jazyce

Objective: HER2 negative carcinomas of the breast pose a challenge for treatment due to redundancies in potential drug targets and poor patient outcomes. Our aim was to investigate the role of L-type amino acid transporter-LAT1 as a potential prognosticator and a drug target. Methods: In this retrospective work, we have studied the expression of LAT1 in 145 breast cancer tissues via immunohistochemistry. Overall survival analysis was used to evaluate patient outcome in various groups of our cohort. Results: Positive LAT1 expression was found in 27 (84.4%) luminal A subtype, 27 (64.3%) luminal B/triple positive subtype, 29 (82.9%) triple negative subtype, and 24 (66.7%) HER2-only positive subtype (p=0.1). Interestingly, negative correlation was found between LAT1 and HER2; where positive expression of LAT1 was found in 56 (83.6%) cases in negative HER2 group and 51 (65.4%) cases from positive HER2 group (p=0.01). Unfortunately, we were unable to report significant survival differences when LAT1 expression was studied in the negative HER2 group. Nevertheless, five incidents of mortality (out of 55) were reported in LAT1+/HER2-group compared to none in the LAT1-/HER2-group (N=11). Conclusion: Our findings of overexpression of LAT1 in negative HER2 group suggest a role of this protein as prognosticator and drug target in a challenging therapeutic cohort.

Název v anglickém jazyce

LAT1 (SLC7A5) overexpression in negative her2 group of breast cancer: A potential therapy target

Popis výsledku anglicky

Objective: HER2 negative carcinomas of the breast pose a challenge for treatment due to redundancies in potential drug targets and poor patient outcomes. Our aim was to investigate the role of L-type amino acid transporter-LAT1 as a potential prognosticator and a drug target. Methods: In this retrospective work, we have studied the expression of LAT1 in 145 breast cancer tissues via immunohistochemistry. Overall survival analysis was used to evaluate patient outcome in various groups of our cohort. Results: Positive LAT1 expression was found in 27 (84.4%) luminal A subtype, 27 (64.3%) luminal B/triple positive subtype, 29 (82.9%) triple negative subtype, and 24 (66.7%) HER2-only positive subtype (p=0.1). Interestingly, negative correlation was found between LAT1 and HER2; where positive expression of LAT1 was found in 56 (83.6%) cases in negative HER2 group and 51 (65.4%) cases from positive HER2 group (p=0.01). Unfortunately, we were unable to report significant survival differences when LAT1 expression was studied in the negative HER2 group. Nevertheless, five incidents of mortality (out of 55) were reported in LAT1+/HER2-group compared to none in the LAT1-/HER2-group (N=11). Conclusion: Our findings of overexpression of LAT1 in negative HER2 group suggest a role of this protein as prognosticator and drug target in a challenging therapeutic cohort.

Druh

J_SC - Článek v periodiku v databázi SCOPUS

CEP obor

—

OECD FORD obor

10608 - Biochemistry and molecular biology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2020

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Asian Pacific Journal of Cancer Prevention

ISSN

1513-7368

e-ISSN

—

Svazek periodika

21

Číslo periodika v rámci svazku

5

Stát vydavatele periodika

TH - Thajské království

Počet stran výsledku

6

Strana od-do

1453-1458

Kód UT WoS článku

—

EID výsledku v databázi Scopus

2-s2.0-85085539666